$LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Healthcare
Sector
Biotechnology
Industry
Carole S. Ben-Maimon
CEO
65
Employees
$4.38
Current Price
$285.02M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 4 | 7 | $25,550,000.00 | 5,110,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 4 | 7 | $25,550,000.00 | 5,110,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 4 | 7 | $25,550,000.00 | 5,110,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Feb 27, 2026 | Flynn James E Director | Purchase | 1,084,010 | $5.00 | $5,420,050.00 | View Details |
| Feb 27, 2026 | Flynn James E Director | Purchase | 1,084,012 | $5.00 | $5,420,060.00 | View Details |
| Feb 27, 2026 | Flynn James E Director | Purchase | 831,978 | $5.00 | $4,159,890.00 | View Details |
| Feb 27, 2026 | Flynn James E Director | Purchase | 2,000,000 | $5.00 | $10,000,000.00 | View Details |
| Feb 27, 2026 | THOMAS FRANK E Director | Purchase | 5,000 | $5.00 | $25,000.00 | View Details |
| Feb 27, 2026 | SHERMAN JEFFREY W Director | Purchase | 5,000 | $5.00 | $25,000.00 | View Details |
| Feb 27, 2026 | Hamilton Thomas Edward Director | Purchase | 100,000 | $5.00 | $500,000.00 | View Details |
3 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated-$0.43
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.55
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
No past earnings data available
Related Activity
Cross-company insider connections and cluster buy signals